The U.S. Food and Drug Administration (FDA) approved orforglipron (Foundayo; Eli Lilly and Company) on April 1, 2026, for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, marking the first regulatory approval globally of an oral small-molecule, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Fig.1 Lilly's official press release announcing FDA approval of Foundayo (orforglipron), April 1, 2026.
Orforglipron is an oral, once-daily small-molecule (non-peptide) GLP-1 RA developed by Eli Lilly and Company (USA), originally discovered by Chugai Pharmaceutical and in-licensed by Lilly in 2018. Unlike peptide-based GLP-1 agents, orforglipron is absorbed without food or water restrictions and requires no cold-chain storage. The approval is supported by the Phase III ATTAIN clinical program, encompassing two global registration studies in more than 4,500 patients. In ATTAIN-1 (NCT05869903), a 72-week, randomized, double-blind, placebo-controlled study in 2,551 adults with obesity or overweight without diabetes, the 36 mg dose achieved a mean body weight reduction of 12.4 kg (12.4%) versus placebo at Week 72; 59.6% of participants achieved ≥10% body weight loss and 39.6% achieved ≥15% weight loss. In ATTAIN-2 (NCT05872620), a parallel 72-week study in adults with obesity or overweight plus type 2 diabetes, orforglipron 36 mg reduced mean body weight by 10.4 kg (10.5%) and lowered glycated hemoglobin (HbA1c) by 1.3%–1.8% from a baseline mean of 8.1%, with 75.0% of patients in the 36 mg group achieving HbA1c ≤6.5%. Both studies also demonstrated improvements in non-high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure. The most common adverse events were gastrointestinal in nature and generally mild to moderate in severity, consistent with the GLP-1 RA class profile.
Foundayo represents Lilly's second FDA-approved obesity medicine and its first approved oral weight management therapy. As the only approved GLP-1 RA available in oral small-molecule form, orforglipron addresses an unmet need for patients who require or prefer a non-injectable treatment option. Lilly is advancing additional Phase III studies of orforglipron in type 2 diabetes, obesity with obstructive sleep apnea, hypertension, and osteoarthritis pain. In China, the National Medical Products Administration's Center for Drug Evaluation accepted the new drug application for orforglipron in January 2026 for type 2 diabetes and obesity; Lilly has also announced plans to invest USD 3 billion in China over ten years to build local oral solid dosage manufacturing capacity, including for orforglipron.